Patent application number | Description | Published |
20090079573 | LARGE SCALE FOLDED DIPOLE ANTENNA FOR NEAR-FIELD RFID APPLICATIONS - In accordance with a preferred embodiment of the invention, reader antennas are provided within storage fixtures or supporting fixtures for transporting RF signals between, for example, an RFID reader and an RFID tag. In a preferred embodiment, the RFID-enabled fixtures are implemented using an intelligent network, which may allow enhanced flexibility in controlling systems for interrogation of RFID antennas. | 03-26-2009 |
20090168753 | RFID NETWORK CONTROL AND REDUNDANCY - In accordance with the preferred embodiment and alternative embodiments of the invention, RFID network control devices (RNCDs) are provided wherein RFID traffic signals from any one of multiple RFID readers may be routed to any of the RFID antennas coupled to the RNCD. Each reader coupled directly or indirectly to the RNCD, either through its own action or the action of the external host controller managing the reader, may issue commands to the RNCD, over the same cable used to carry RFID traffic signals, and cause the RNCD to set its internal switch configuration such that a channel is established for RFID traffic signals between that reader and a particular RFID antenna coupled to the RNCD. This may include commands from the reader or external host controller which place other intervening RNCD units in a bypass state so as to establish the required communications channel with a minimum of signal strength loss. | 07-02-2009 |
20090213012 | RFID PATCH ANTENNA WITH COPLANAR REFERENCE GROUND AND FLOATING GROUNDS - In accordance with a preferred embodiment of the invention, reader antennas are provided within storage fixtures for transporting RF signals between, for example, an RFID reader and an RFID tag. In a preferred embodiment, the RFID-enabled storage fixtures are implemented using an intelligent network, which may allow enhanced flexibility in controlling systems for interrogation of RFID antennas. | 08-27-2009 |
20090295645 | BROADBAND ANTENNA WITH MULTIPLE ASSOCIATED PATCHES AND COPLANAR GROUNDING FOR RFID APPLICATIONS - Described herein is an antenna for use with a radio frequency identification system, the antenna including a reference ground; an antenna feed; a primary patch antenna element for mid-field transmission and reception of one of HP and UHF signals, wherein the primary patch antenna element is electrically coupled to the antenna feed; and one or more additional patch antenna elements for mid-field transmission and reception of the one of HF and UHF broadband signals, wherein each of the one or more additional patch antenna elements is electrically connected to an edge of the primary patch antenna element for transmission and reception of the one of HF and UHF signals. The one or more additional patch antenna elements provide for gain enhancement of the one of HF and UHF signals. | 12-03-2009 |
20100194524 | Home Network Control Node for Device Control and Energy Conservation - It may be desirable to reduce the energy consumption of a home or commercial building to control energy costs or to ensure that the energy consumption does not exceed what is available in non-conventional energy systems such as solar power systems. The present invention relates to a system of network control nodes that can be used to monitor and control devices such as appliances and lights to ensure that the power consumption of the entire network is within the established target levels. | 08-05-2010 |
20110273360 | COMBINATION RADIO FREQUENCY IDENTIFICATION AND ELECTRONIC ARTICLE SURVEILLANCE ANTENNA SYSTEM - An RFID antenna for use in an RFID-EAS antenna system is disclosed. In one embodiment, the RFID antenna has a first patch antenna element and a second patch antenna element that are electrically connected and coplanar. The RFID antenna also has a reference ground plane coplanar with the patch antenna elements. | 11-10-2011 |
20120018504 | Tag having three component unitary pole antenna - A tag has antenna system includes three antenna portions. Each of the three antenna portions has a ½ dipole structure. A fourth antenna portion is shorted to the non-linear device. The antenna is tuned to an operating frequency by modifying the electrical lengths of one, two, or all three antenna portions. Preferably, the invention includes an inductive portion, such as a slot inductive portion. The antenna portions are configured in any desired form, such as being spiral or otherwise compacted, for particular operational parameters in a limited space. | 01-26-2012 |
20120018505 | Tag having dipole-loop antenna - A tag has a dipole and loop antenna. | 01-26-2012 |
20120139709 | RFID NETWORK CONTROL AND REDUNDANCY - In accordance with embodiments of the invention, RFID network control devices (RNCDs) are provided wherein RFID traffic signals from any one of multiple RFID readers may be routed to any of the RFID antennas coupled to the RNCD. Each reader coupled directly or indirectly to the RNCD, either through its own action or the action of the external host controller managing the reader, may issue commands to the RNCD, over the same cable used to carry RFID traffic signals, and cause the RNCD to set its internal switch configuration such that a channel is established for RFID traffic signals between that reader and a particular RFID antenna coupled to the RNCD. This may include commands from the reader or external host controller which place other intervening RNCD units in a bypass state so as to establish the required communications channel with a minimum of signal strength loss. | 06-07-2012 |
20120262353 | SMALL BROADBAND LOOP ANTENNA FOR NEAR FIELD APPLICATIONS - A method and apparatus for providing a broadband near field of an antenna are disclosed. A small broadband loop antenna may include a printed circuit board (PCB) substrate with multiple layers. Printed on the PCB substrate are dual loops sharing a same driver circuit, an impedance matching network, a primary ground layer and a conductive layer. A shorting via connects the dual loops to a ground plane. The antenna may be tuned to a desired operating frequency by adjusting parameters of the loop, such as the position of the shorting via. | 10-18-2012 |
Patent application number | Description | Published |
20080286359 | Low Dosage Forms Of Risedronate Or Its Salts - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 11-20-2008 |
20080287400 | Low Dosage Forms Of Risedronate Or Its Salts - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 11-20-2008 |
20100086593 | DOSAGE FORMS OF BISPHOSPHONATES - Oral dosage forms of a bisphosphonate comprised of a safe and effective amount of a pharmaceutical composition comprising a bisphosphonate, a chelating agent, and, means for effecting delayed release of the bisphosphonate and the chelating agent in the lower gastrointestinal tract provide delivery of the pharmaceutical composition to the lower gastrointestinal tract of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 04-08-2010 |
20100113394 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 05-06-2010 |
20100113395 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 05-06-2010 |
20100119559 | DOSAGE FORMS OF RISEDRONATE - Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 05-13-2010 |
20120094960 | DOSAGE FORMS OF RISEDRONATE - Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 04-19-2012 |
20130012478 | DOSAGE FORMS OF BISPHOSPHONATES - Provided is an oral dosage form comprising a bisphosphonate selected from the group consisting of a risedronate and salts thereof; an ethylenediaminetetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof; and a delayed release mechanism to deliver the risedronate and the EDTA in the lower gastrointestinal tract, wherein the oral dosage form is administered according to a scheduled dosing interval. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 01-10-2013 |
20130177645 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 07-11-2013 |
20130183353 | LOW DOSAGE FORMS OF RISEDRONATE OR ITS SALTS - Oral dosage forms comprising risedronate or a salt thereof, a chelating agent, and means for effecting delayed release of the risedronate (or salt) immediate release of the oral dosage form to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between the risedronate (or salt) and food or beverages, which interaction results in the active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, disclosed is delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 07-18-2013 |
20130331361 | DOSAGE FORMS OF BISPHOSPHONATES - Provided is an oral dosage form comprising a bisphosphonate selected from the group consisting of a risedronate and salts thereof; an ethylenediaminetetraacetic acid (EDTA) or a pharmaceutically acceptable salt thereof; and a delayed release mechanism to deliver the risedronate and the EDTA in the lower gastrointestinal tract, wherein the oral dosage form is administered according to a scheduled dosing interval. The present invention substantially alleviates the interaction between bisphosphonates and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of the bisphosphonate and the chelating agent to the lower GI tract, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 12-12-2013 |
20140057872 | DOSAGE FORMS OF RISEDRONATE - Oral dosage forms of a risedronate comprised of a safe and effective amount of a pharmaceutical composition comprising risedronate, a chelating agent, and, means for effecting delayed release of the risedronate and the chelating agent in the small intestine provide immediate release of the pharmaceutical composition to the small intestine of the mammal subject and pharmaceutically effective absorption of the bisphosphonate with or without food or beverages. The present invention substantially alleviates the interaction between risedronate and food or beverages, which interaction results in the bisphosphonate active ingredient not being available for absorption. The resulting oral dosage form may thus be taken with or without food. Further, the present invention effects delivery of risedronate and the chelating agent to the small intestine, substantially alleviating the upper GI irritation associated with bisphosphonate therapies. These benefits simplify previously complex treatment regimens and can lead to increased patient compliance with bisphosphonate therapies. | 02-27-2014 |
20160081943 | Process For Making A Core With An Active Coating - Forming a coated core by using a fluidized bed processor that discharges a spray containing atomized air and a coating solution where the coating solution contains an active. Then, wetting the core with the coating solution and drying the wetted cores to form coated cores. These steps can be repeated until an appropriate amount of active has been applied. The coated cores are visually perceived as smooth under a microscope with a total magnification of 40×. | 03-24-2016 |
20160081948 | Pulsed Release Phenylephrine Dosage Forms - A multi-particle dosage form that can deliver phenylephrine in controlled pulsed doses. The dosage form can contain an immediate release form that can contain phenylephrine or a salt thereof and a plurality of delayed release particles with a coating that can contain phenylephrine or salt thereof and a pH sensitive coating. | 03-24-2016 |
Patent application number | Description | Published |
20120036892 | AIR SEPARATION METHOD AND APPARATUS - An air separation method and apparatus in which a supercritical oxygen product is produced by heating a pumped liquid oxygen stream having a supercritical pressure, through indirect heat exchange with a boosted pressure air stream. The indirect heat exchange is conducted within a heat exchanger and a liquid nitrogen stream is vaporized in the heat exchanger to depress the pressure that would otherwise be required of the boosted pressure air stream to heat the pumped liquid oxygen stream. The pumped liquid oxygen stream constitutes 90 percent of the oxygen-rich liquid removed from an air separation unit in which the air is rectified, the liquid nitrogen constitutes at least 90 percent of the liquid nitrogen that is not used as reflux and a flow-rate ratio between the liquid nitrogen stream and the oxygen-rich liquid is between about 0.3 and 0.90. | 02-16-2012 |
20130129531 | MULTISTAGE COMPRESSOR INSTALLATION - A multistage compressor installation in which compression stages utilizing centrifugal compressors are independently driven by drivers that can be electric motors configured to be controlled by a speed controller. Intercoolers are located between stages to remove the heat of compression and the stages are connected such that outlets are located opposite to inlets of the compressors and conduits connecting the intercoolers to the stages are in an in-line relationship to inhibit the formation of pressure drops between stages. The conduits connecting the stages incorporate tapered transition sections configured such that flow velocity gradually decreases towards the intercooler and gradually increases from the intercooler to the next succeeding compression stage to further inhibit pressure drops. | 05-23-2013 |
20140165650 | HEAT EXCHANGER AND DISTILLATION COLUMN ARRANGEMENT - A shell and tube heat exchanger and distillation column arrangement for an air separation plant utilizing such heat exchanger in which tubes for passage of a liquid that is used in condensing a vapor are located within a cylindrical shell. The tubes are arranged in an inner array of tubes and an outer array of tubes surrounding the inner array of tubes and having more tubes than the inner array. The inner array of tubes present a larger average area, between tubes, for flow of the vapor in an outward, radial direction than tubes of the outer array to lessen pressure drop while allowing for more tubes to be located within the shell to increase the surface area available for heat exchange between the liquid and the vapor. | 06-19-2014 |
20140208799 | APPARATUS AND AIR SEPARATION PLANT - The present invention relates to an apparatus and air separation plant in which a pumped liquid oxygen stream is heated within a heat exchanger through indirect heat exchange with compressed air to produce an oxygen product. The liquid oxygen stream is pressurized in a range above about 55 bar(a) and no greater than about 150 bar(a) and is a supercritical fluid after having been heated within the heat exchanger. The air is compressed to an air pressure that is a function of the oxygen pressure that will result in a minimum power being expended in the compression of the air. The heat exchanger can be a brazed fin heat exchanger fabricated from aluminum in which the fins located in heat exchange passages have an undulating configuration to increase the flow path length and induce flow separation and thereby increase the heat transfer coefficient within the heat exchanger. | 07-31-2014 |
20150267962 | INSULATION ARRANGEMENT - An arrangement of insulation within a container to prevent heat leakage from the ambient to an apparatus located within the container that operates at a cryogenic temperature. The arrangement of insulation includes bulk insulation filling the container and an insulation layer that is located within the container, between the apparatus and the container. The insulation layer as opposed to the bulk insulation has a lower thermal conductivity. An exterior region of the apparatus is situated closer to an opposite container wall region of the container than remaining exterior regions of the apparatus. The insulation layer is sized to only insulate the exterior region of the apparatus from heat leakage from the opposite container wall region. The insulation layer can be formed of an aerogel. | 09-24-2015 |
Patent application number | Description | Published |
20090143745 | SAFETY DEVICE FOR DRUG DELIVERY DEVICES AND CONTAINERS - A drug administration safety device having a label configured to be attached to a drug container such as a syringe or IV bag, an adhesive on the back face of the label, and a backing or substrate for holding the label and protecting the adhesive prior to the application of the label to the drug container. In one embodiment, the label includes a first drug name section in a first orientation, a second drug name section in a second orientation, a third drug name section in a third orientation, a drug concentration section, a variable information section, and a gradiation viewing section. The first orientation, second orientation, and third orientation are different from each other to enable a user to readily see the drug name regardless of the position and orientation of the drug container. | 06-04-2009 |
20110152834 | SAFETY DEVICE FOR DRUG DELIVERY DEVICES AND CONTAINERS - A drug administration safety device having a label configured to be attached to a drug container such as a syringe or IV bag, an adhesive on the back face of the label, and a backing or substrate for holding the label and protecting the adhesive prior to the application of the label to the drug container. In one embodiment, the label includes a first drug name section in a first orientation, a second drug name section in a second orientation, a third drug name section in a third orientation, a drug concentration section, a variable information section, and a gradiation viewing section. The first orientation, second orientation, and third orientation are different from each other to enable a user to readily see the drug name regardless of the position and orientation of the drug container. | 06-23-2011 |
20130274675 | SAFETY DEVICE FOR DRUG DELIVERY DEVICES AND CONTAINERS - A drug administration safety device having a label configured to be attached to a drug container such as a syringe or IV bag, an adhesive on the back face of the label, and a backing or substrate for holding the label and protecting the adhesive prior to the application of the label to the drug container. In one embodiment, the label includes a first drug name section in a first orientation, a second drug name section in a second orientation, a third drug name section in a third orientation, a drug concentration section, a variable information section, and a gradiation viewing section. The first orientation, second orientation, and third orientation are different from each other to enable a user to readily see the drug name regardless of the position and orientation of the drug container. | 10-17-2013 |
20130289496 | Intravenous Bag/Line Safety Device - An IV bag/line safety device including a tag set and a bag attacher removably connected to the tag set. The tag set includes a plurality of tags printed with the name of an IV solution. The bag attacher is configured to attach the safety device to an IV bag containing the IV solution printed on the tags. After attachment, the safety device provides visual cues to a user inviting the user to disconnect the tags from the safety device. After disconnecting one or more of the tags, the user may attach those tags to an IV tubing line connected to the IV bag through which the IV solution contained in the IV bag flows from the IV bag into a patient. This enables the user to quickly identify a given IV tubing line having at least one tag attached thereto as containing a particular IV solution. | 10-31-2013 |
20140090226 | Intravenous Bag/Line Safety Device - An IV bag/line safety device including a tag set and a bag attacher removably connected to the tag set. The tag set includes a plurality of tags printed with the name of an IV solution. The bag attacher is configured to attach the safety device to an IV bag containing the IV solution printed on the tags. After attachment, the safety device provides visual cues to a user inviting the user to disconnect the tags from the safety device. After disconnecting one or more of the tags, the user may attach those tags to an IV tubing line connected to the IV bag through which the IV solution contained in the IV bag flows from the IV bag into a patient. This enables the user to quickly identify a given IV tubing line having at least one tag attached thereto as containing a particular IV solution. | 04-03-2014 |
20140326629 | INTRAVENOUS BAG/LINE SAFETY DEVICE - An IV bag/line safety device including a tag set and a bag attacher removably connected to the tag set. The tag set includes a plurality of tags printed with the name of an IV solution. The bag attacher is configured to attach the safety device to an IV bag containing the IV solution printed on the tags. After attachment, the safety device provides visual cues to a user inviting the user to disconnect the tags from the safety device. After disconnecting one or more of the tags, the user may attach those tags to an IV tubing line connected to the IV bag through which the IV solution contained in the IV bag flows from the IV bag into a patient. This enables the user to quickly identify a given IV tubing line having at least one tag attached thereto as containing a particular IV solution. | 11-06-2014 |
Patent application number | Description | Published |
20090034910 | Optical Connections And Methods Of Forming Optical Connections - In one embodiment, an assembly having a first board, a second board, a fiber bundle, and at least one movable stage is provided. The fiber bundle has a first end and a second end, and the first end of the fiber bundle is attached to the first board first face. The movable stage has a second optical array provided thereon or therein. The movable stage is disposed on the second board such that the at least one motor steers the movable stage. The movable stage is steered such that the second optical array is aligned with the second end of the fiber bundle in a desired manner. | 02-05-2009 |
20100074294 | APPARATUS AND METHOD OF ESTABLISHING OPTICAL COMMUNICATION CHANNELS BETWEEN A STEERABLE ARRAY OF LASER EMITTERS AND AN ARRAY OF OPTICAL DETECTORS - An array of light beam emitter sections comprises: a substrate having a surface divided into an array of sections; and a grouping of light emitters disposed at each surface section and configured to emit light beams at different emission angles with respect to the surface. Also disclosed is apparatus for establishing optical communication channels between the array of light beam emitter sections and an array of light detectors. Further disclosed is a method of establishing optical communication channels between the array of light emitter sections and the array of light detectors by mapping at least one light emitter of each grouping with a light detector of the detector array to establish optical communication channels between the arrays based on the mappings. | 03-25-2010 |
20100074576 | Optical Connections And Methods Of Forming Optical Connections - In one embodiment, method of forming fibers is provided. The method includes modifying a first exposed edge of at least one core of a first fiber. The first fiber has a first end, a second end, and a length between the first end and the second end. The second end has the first exposed edge of the core, and the first exposed edge has a first diffusion state. The first fiber may transmit light along the core. The modification of the first exposed edge includes modifying the first diffusion state of the first exposed edge of the core to a second diffusion state such that light exiting the first exposed edge in the second diffusion state is spread over a greater number of angles relative to angles of the light exiting the first exposed edge in the first diffusion state. | 03-25-2010 |
20100150502 | Optical Connections And Methods Of Forming Optical Connections - In one embodiment, an assembly having a first board, a second board, a fiber bundle, and at least one movable stage is provided. The fiber bundle has a first end and a second end, and the first end of the fiber bundle is attached to the first board first face. The movable stage has a second optical array provided thereon or therein. The movable stage is disposed on the second board such that the at least one motor steers the movable stage. The movable stage is steered such that the second optical array is aligned with the second end of the fiber bundle in a desired manner. | 06-17-2010 |
20100322552 | OPTICAL CONNECTIONS AND METHODS OF FORMING OPTICAL CONNECTIONS - In one embodiment, a system comprises a plurality of electronic circuit boards and at least one optical fiber in optical communication with at least one circuit board of the plurality of electronic circuit boards, wherein at least one optical fiber comprises at least one core having at least one end surface, and wherein at least one end surface comprises a light dispersing geometry. | 12-23-2010 |
Patent application number | Description | Published |
20100106674 | Method and system for integrated analysis - A system and method of analysis, including, but not limited to: receiving raw data related to at least one project; receiving user preferences in at least one workflow, wherein each step in the a workflow constitutes a single instance of a component of a workflow such that the state of a unique component is always the same if the same component is comprised in other workflows; determining metrics related to the at least one project; analyzing the data & metrics to identify patterns; drawing conclusions from the data, metrics and patterns; and generating at least one report that presents the metrics, patterns and conclusions. | 04-29-2010 |
20120016638 | METHOD AND SYSTEM FOR INTEGRATED ANALYSIS - A system and method of analysis, including, but not limited to: receiving raw data related to at least one project; receiving user preferences in at least one workflow, wherein each step in the a workflow constitutes a single instance of a component of a workflow such that the state of a unique component is always the same if the same component is comprised in other workflows; determining metrics related to the at least one project; analyzing the data & metrics to identify patterns; drawing conclusions from the data, metrics and patterns; and generating at least one report that presents the metrics, patterns and conclusions. | 01-19-2012 |
20120271784 | METHOD AND SYSTEM FOR INTEGRATED ANALYSIS - A system and method of analysis, including, but not limited to: receiving raw data related to at least one project; receiving user preferences in at least one workflow, and determining metrics related to the, at least one project. | 10-25-2012 |